AU2013328393A1 — Stable injectable pharmaceutical composition of epinephrine or salts thereof
Assigned to Wockhardt Ltd · Expires 2015-04-09 · 11y expired
What this patent protects
The present invention refers to a stabilized injectable pharmaceutical composition of epinephrine or salts thereof comprising sodium metabisulfite, wherein the ratio of the amount of epinephrine or salt thereof to sodium metabisulfite in the composition ranges from about 1 :0.005…
USPTO Abstract
The present invention refers to a stabilized injectable pharmaceutical composition of epinephrine or salts thereof comprising sodium metabisulfite, wherein the ratio of the amount of epinephrine or salt thereof to sodium metabisulfite in the composition ranges from about 1 :0.005 to about 1:1.5 by weight. It has been observed that stable injectable epinephrine compositions with excellent storage stability and substantially free of overages can be prepared using sodium metabisulfite in said ratios. Particularly, it was found that using sodium metabisulfite in said ratios controls levels of adrenaline sulfonate impurity in said pharmaceutical compositions.
Drugs covered by this patent
- Levophed (Norepinephrine Bitartrate) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.